Fabric Genomics Inc.

Fabric Genomics Inc. is a US-based company specializing in advanced genomic testing solutions that leverage AI algorithms. Their innovative platform streamlines the interpretation of next-generation sequencing data for clinical applications in healthcare. Founded in 2009 and headquartered in Oakland, US, Fabric Genomics Inc.

focuses on genomic testing solutions. The company was established by Martin Reese, who has an extensive background in biotechnology. Fabric Genomics has engaged in 4 funding rounds, with its most recent funding event being a TRADE SALE on April 15, 2025, where GeneDx, LLC. acquired the company for USD 33.

00 mn, with potential additional payments of up to USD 18. 00 mn based on milestone achievements. Fabric Genomics specializes in genomic testing solutions powered by advanced AI algorithms, primarily through its Fabric Enterprise platform. This platform enables the rapid interpretation of next-generation sequencing (NGS) data across various clinical applications, including inherited diseases, rare diseases, and oncology.

By combining deep phenotype data with genotype information using machine learning techniques, Fabric Genomics enhances diagnostic yields, achieving results up to 50% in difficult diagnostic odyssey cases compared to the industry average. Their services are designed to facilitate rapid, physician-ready clinical reporting, with reports generated in less than two hours for whole genome sequencing. The company's client base includes clinical laboratories, hospital systems, and national sequencing programs across multiple geographical markets, including the United States, the United Kingdom, and select countries in Europe and Asia. Fabric Genomics generates revenue primarily through partnerships with clinical laboratories and hospital systems, structured around service agreements for their Fabric Enterprise platform.

Clients typically engage Fabric Genomics via subscription models or contractual partnerships, utilizing their diagnostic services as part of broader genomic testing programs. The company's flagship service offerings include whole genome sequencing (WGS) interpretation and hereditary disease panels, which enable quick and accurate clinical reporting. Pricing plans are structured around the complexity and volume of tests, with specific financial details associated with individual services directly tied to client agreements. Through these business transactions, Fabric Genomics facilitates the integration of genomic insights into clinical care, helping healthcare providers enhance patient outcomes.

In April 2025, Fabric Genomics will be acquired by GeneDX, LLC, which aims to leverage its new acquisition to expand scalable revenue streams like decentralized testing with centralized intelligence. This strategic move is part of GeneDX's plan to integrate and enhance genomic testing capabilities in various markets. The investment from the acquisition will support the expansion into new geographic regions and further development of innovative products, although specific details on upcoming products or additional market entries have not been disclosed.